Please login to the form below

Not currently logged in
Email:
Password:

Jardiance

This page shows the latest Jardiance news and features for those working in and with pharma, biotech and healthcare.

AZ’s Farxiga cuts risk of death in chronic kidney disease

AZ’s Farxiga cuts risk of death in chronic kidney disease

In March, the US Food and Drug Administration (FDA) fast-tracked Farxiga’s rival Jardiance (empagliflozin), co-developed by Eli Lilly and Boehringer Ingelheim, to reduce the risk of kidney disease ... Lilly/Boehringer are studying Jardiance in the

Latest news

More from news
Approximately 26 fully matching, plus 62 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    The remaining two SGLT2s are growing faster than the market, with Jardiance (empagliflozin) leading the market in terms of growth. ... In contrast Jardiance and Vipidia are still growing where Jardiance (the 3rd entrant SGLT2) appears to have overtaken

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics